Novogen subsidiary files IND
Tuesday, 02 December, 2008
Novogen’s US subsidiary Marshall Edwards has filed an investigational new drug (IND) application with the US FDA for its chemo-sensitising agent triphendiol.
Triphendiol - to be used in conjunction with gemcitabine, a nucleoside analogue marketed by Eli Lilly as Gemzar – was granted orphan drug status in January for treatment of pancreatic cancer.
The IND application is to enable a Phase I study in patients with unresectable or metastatic pancreatic and bile duct cancers.
Marshall Edwards’ lead candidate, phenoxodiol, is in Phase III trials for recurrent ovarian cancer.
Novogen has licensed both triphendiol and phenoxodiol to Marshall Edwards, and is now looking at another compound, the mTOR inhibitor NV-128, to act against cancer stem cells.
The compound induces caspase-independent apoptosis via the AKT-mTOR pathway and is being investigated for its action against rapidly dividing cells in solid tumours.
A collaboration with a team from Yale University has found the compound has a high level of potency against cancer stem cells, the company said.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
